The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse

Endocrinology
F NicolettiG Garotta

Abstract

Previous studies have shown that in vivo treatment with antiinterferon-gamma (anti-IFNgamma) monoclonal antibodies (mAbs) prevents the development of autoimmune diabetes in NOD mice. Although these findings anticipate that specific anti-IFNgamma therapies may be useful for the prevention/treatment of human insulin-dependent diabetes mellitus, there are several reasons why the use of anti-IFNgamma mAb may be difficult in the clinical setting. With the aim to develop alternative forms of specific anti-IFNgamma therapies, we recently produced a nonimmunogenic form of the soluble IFNgamma receptor (sIFNgammaR) that binds and neutralizes murine IFNgamma with an affinity higher than that of anti-IFNgamma mAb. In this study we compared the efficacy of sIFNgammaR to that of two anti-IFNgamma mAbs (XMG 1.2 and AN-18) in the prevention of spontaneous and accelerated (cyclophosphamide-induced) forms of autoimmune diabetes in NOD mice. The results show that in the spontaneous model, sIFNgammaR could prevent histological and clinical signs of autoimmune diabetes as efficiently as the two mAbs. Under ex vivo conditions, sIFNgammaR exhibited a more powerful modulatory effect than XMG 1.2 mAb on cytokine secretion from splenic lymphoid cells, ...Continue Reading

Citations

Sep 12, 2012·Cell Research·Jun-Bao Fan, Dong-Er Zhang
Jun 27, 2012·Proceedings of the National Academy of Sciences of the United States of America·Li-Fen LeeJohn C Lin
Jul 21, 2000·The Journal of Clinical Investigation·B R LawsonA N Theofilopoulos
Sep 17, 1998·The Journal of Clinical Investigation·H E ThomasT W Kay
Feb 4, 2009·The Journal of Clinical Investigation·David BendingAnne Cooke
Aug 2, 2003·International Immunopharmacology·Heiko Mühl, Josef Pfeilschifter
Aug 23, 2002·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·P B SugermanM Bigby
Apr 14, 2015·European Journal of Immunology·Tiago AmadoAnita Q Gomes
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F NicolettiP Meroni
Oct 15, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Paul C DimayugaBojan Cercek
Mar 25, 2005·European Journal of Immunology·Marcelo De Carvalho BittencourtMarie H Kosco-Vilbois
Aug 10, 2000·Diabetes/metabolism Research and Reviews·H E Thomas, T W Kay
Feb 5, 1999·European Journal of Immunology·I André-SchmutzD Mathis
May 4, 2017·Immunology and Cell Biology·Jennifer Y BarrScott M Lieberman
Feb 25, 2000·Allergy·G Tau, P Rothman
Sep 3, 2002·Clinical and Diagnostic Laboratory Immunology·Erik L MunsonRonald F Schell
Feb 16, 2011·Immunology and Cell Biology·Tejas PatelSundararajan Jayaraman
Dec 11, 2014·Advanced Healthcare Materials·Veronika KozlovskayaEugenia Kharlampieva
Dec 8, 2017·Journal of Cellular Physiology·Milica VujicicStanislava Stosic-Grujicic
Jan 18, 2013·Annals of the New York Academy of Sciences·Lindsey E PadgettHubert M Tse
Oct 16, 2015·The Journal of Biological Chemistry·Ming-Wei ChienHuey-Kang Sytwu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.